Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
Scheck MK, Goetze TO, Ettrich TJ, Schmalenberg H, Clemens M, Mahlberg R, Heeg S, Kanzler S, Hapke G, Thuss-Patience P, Kestler A, Treschl A, Heidel S, Schiemer M, Sookthai D, Junge S, Pauligk C, Al-Batran SE, Lorenzen S. Scheck MK, et al. Among authors: treschl a. Oncol Res Treat. 2024;47(11):549-560. doi: 10.1159/000541174. Epub 2024 Sep 9. Oncol Res Treat. 2024. PMID: 39250905 Clinical Trial.
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). Horisberger K, et al. Among authors: treschl a. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1487-93. doi: 10.1016/j.ijrobp.2008.10.014. Epub 2009 Jan 7. Int J Radiat Oncol Biol Phys. 2009. PMID: 19131187 Clinical Trial.
mRNA expression of platelet-derived growth factor receptor-beta and C-KIT: correlation with pathologic response to cetuximab-based chemoradiotherapy in patients with rectal cancer.
Erben P, Horisberger K, Muessle B, Müller MC, Treschl A, Ernst T, Kähler G, Ströbel P, Wenz F, Kienle P, Post S, Hochhaus A, Willeke F, Hofheinz RD. Erben P, et al. Among authors: treschl a. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1544-50. doi: 10.1016/j.ijrobp.2008.08.013. Int J Radiat Oncol Biol Phys. 2008. PMID: 19028276